Tenecteplase in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion

Activity: Talk or presentation types › Poster presentation

Description

Recently, a new thrombolytic drug, Tenecteplase, has proved its effectiveness. It is used before thrombectomy in patients with acute ischemic stroke (AIS) due to large vessel occlusion (LVO). Studies show that Tenecteplase is associated with a higher reperfusion rate and better clinical and functional outcomes than Alteplase. This study aims to investigate the functional outcome and the frequency of recanalization before endovascular treatment (EVT) in patients who received thrombolytic therapy with Tenecteplase at Riga East University Hospital (REUH).. The study included data from 39 patients admitted to REUH with a diagnosis of AIS due to LAO and receiving thrombolytic therapy with Tenecteplase. Data about neurological symptoms, functional outcome, complications, and recanalization rates were analyzed retrospectively from medical records.. A total of 39 patients received thrombolytic therapy with Tenecteplase (demographic characteristics – mean age 75.1; women 53.8%). At admission NIHSS was (median) 17 (IQR 20-12) and mRS was (median) 5. Thrombectomy was performed in 48.7% (19) of patients. Before EVT, recanalization was observed in 7.7% (3) patients. Due to anatomical features, access difficulties and other reasons, invasive angiography with subsequent thrombectomy was not performed in 43.6% (17) patients. Successful reperfusion (TICI 2b-3) was achieved in 100% (22) of patients. Hemorrhagic transformation was observed in only 2.6% (1) of patients. Fatal outcomes were 10.2% (4). At discharge, NIHSS was (median) 7 (IQR 10-3) and mRS was (median) 4. Good functional outcome (number of patients reaching mRS 0-3 at discharge) reaches 38.5% (15). . In REUH hospitalized patients with AIS due to large vessel occlusion who received thrombolytic therapy with Tenecteplase, recanalization before EVT was observed in 7.7% of patients and a good functional outcome, i.e. mRS 0-3 at the time of discharge reached 38.5% of patients.
Period29 Mar 2023
Event titleRSU International Research Conference 2023: Knowledge for Use in Practice
Event typeConference
OrganiserRīga Stradiņš University
LocationRiga, LatviaShow on map
Degree of RecognitionInternational

Related content